FDG‐PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma

Abstract

FDG-PET may help to predict outcomes of infield tumour control following palliative RT for treatment of HCC bone metastases. Tumours with low metabolic uptake before RT or with a minor decline in post-RT SUV-ratio showed poor long-term infield tumour control.

Cholecystectomy is associated with higher risk of early recurrence and poorer survival after curative resection for early stage hepatocellular carcinoma

“…In addition, the most common extrahepatic metastatic sites of HCC are lung, abdominal lymph nodes, bone and adrenal gland, direct invasion or metastasis to the gallbladder is rare 42 45 . It has been suggested that gallbladder cancer can easily invade the liver because there is no peritoneum between the gallbladder and the liver fossa.…”

Emerging role of18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma

“…They showed that patients having HCCs of SUV ≥ 2.5 (80%; 16 out of 20 patients) had significantly higher objective response rate to radiotherapy than those with HCCs of SUV < 2.5 (40%; 6 out of 15 patients). Choi et al[101] have retrospectively reviewed 45 metastatic bone lesions in 22 HCC patients treated with radiotherapy. They also revealed significantly better infield progression-free survival and infield event-free survival in tumors with SUV of ≥ 3.0 compared to those in tumors with SUV of < 3.0 (1-year progression-free survival, 88% vs 34%; 1-year event-free survival, 82% vs 52%).…”

FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non–small-cell Lung Cancer

“…18 An in-field event was defined as the first event at an irradiated site, including SREs and recurrent pain intractable to oral opioid use. 18 The primary endpoints of our study were the interval to radiographic progression (progression-free survival [PFS], defined as the interval from the first RT session to in-field PD) and the interval to an in-field event (event-free survival [EFS], defined as the interval from the first RT session to an in-field SRE). A secondary endpoint was bone survival (BS), defined as the interval from the initial diagnosis of bone metastasis to death.…”